EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced Malignancies

Aung Naing iD, Milind Javle, May Cho, Olumide Gbolahan, Omar Alkharabsheh, Fiona Thistlethwaite, Christiane Jungels, Kyriakos P Papadopoulos iD, Jean-Luc Canon, Steven McCune, Sven Gogov, LuLu Cheng und 5 weitere

Journal of Immunotherapy and Precision Oncology · 2027-02 · 10 (1) · 8-19

DOI: 10.36401/jipo-26-27 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, 2027-02. Verfasst von Aung Naing und 16 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Arginase is overexpressed in many advanced cancers, which can deplete arginine in tumors to promote immunosuppression. Arginase inhibition may enhance the efficacy of standard chemotherapy regimens by increasing arginine levels and modulating arginine-mediated immune function. INCB001158 is a potent and selective arginase inhibitor that was assessed in combination with chemotherapy.

Methods

This was an open-label, nonrandomized, phase 1/2 dose-escalation/expansion study in adults with advanced or metastatic solid tumors. INCB001158 was administered orally twice daily (bid) in combination with chemotherapy (mFOLFOX6, gemcitabine/cisplatin, or paclitaxel). Phase 2 tumor-type cohorts were colorectal cancer, biliary tract cancer (BTC), ovarian cancer (OC), gastroesophageal cancer, and endometrial cancer. Primary end points included safety, tolerability, and overall response rate (ORR).

Results

Fifty-four patients were enrolled in phase 1 and 95 in phase 2. No dose-dependent adverse event trends were observed. Recommended phase 2 dose of INCB001158 was 100 mg bid. Two phase 2 expansion cohorts met criteria for Simon 2-stage expansion: patients with BTC treated with INCB001158 100 mg bid plus gemcitabine/cisplatin, and patients with platinum-resistant OC treated with INCB001158 100 mg bid plus paclitaxel. The overall response rate was 24.2% (8/33 patients, all partial responses) in the BTC cohort and 16.7% (1/24 complete response and 3/24 partial responses) in the OC cohort. Pharmacodynamic increase in arginine levels was observed systemically in blood plasma and locally detected by mass-spectrometry images of tumor tissue.

Conclusions

INCB001158 was generally well tolerated and associated with increases in arginine levels and responses in the BTC cohort, suggesting that combination regimens with chemotherapy may provide clinical benefit for some patients. ClinicalTrials.gov ID: NCT03314935; EudraCT 2017–002904-29

Schlagwörter

Stichwörter der Autor:innen

biliary tract cancerimmune modulatoryovarian cancersolid tumortumor microenvironment

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of California Irvine, Orange, CA, USA.
  • Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA.
  • Current: Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
  • The Christie NHS Foundation Trust and University of Manchester, Manchester, UK.

ORCID-Profile: Aung Naing, Kyriakos P Papadopoulos

Zitieren

APA

Naing, A., Javle, M., Cho, M., Gbolahan, O., Alkharabsheh, O., Thistlethwaite, F., Jungels, C., Papadopoulos, K. P., Canon, J. L., McCune, S., Gogov, S., Cheng, L., Dong, Z., Gong, X., Ioannidis, S., Kristeleit, R., & Bridgewater, J. (2027). Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced Malignancies. Journal of Immunotherapy and Precision Oncology, 10(1), 8-19. https://doi.org/10.36401/jipo-26-27

Vancouver

Naing A, Javle M, Cho M, Gbolahan O, Alkharabsheh O, Thistlethwaite F, et al. Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced Malignancies. Journal of Immunotherapy and Precision Oncology. 2027;10(1):8-19. doi:10.36401/jipo-26-27

BibTeX
@article{Naing2027,
  author = {Naing, Aung and Javle, Milind and Cho, May and Gbolahan, Olumide and Alkharabsheh, Omar and Thistlethwaite, Fiona and Jungels, Christiane and Papadopoulos, Kyriakos P and Canon, Jean-Luc and McCune, Steven and Gogov, Sven and Cheng, LuLu and Dong, Zhiwan and Gong, Xiaohua and Ioannidis, Sonia and Kristeleit, Rebecca and Bridgewater, John},
  title = {Releasing Immunosuppression in the Tumor: A Phase 1/2 Study of Arginase Inhibitor INCB001158 in Combination with Chemotherapy in Advanced Malignancies},
  journal = {Journal of Immunotherapy and Precision Oncology},
  year = {2027},
  volume = {10},
  number = {1},
  pages = {8--19},
  doi = {10.36401/jipo-26-27}
}
Kostenlos starten →